(Q37856782)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21431303%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

review article

1 reference

title

Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21431303%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21431303%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

4

Ewa Paleolog

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21431303%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

2

Serafim Kiriakidis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21431303%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Peter Dawson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21431303%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

23 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21431303%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21431303%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21431303%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21431303%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

223-234

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21431303%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10456-011-9208-2

26 January 2020

exact match

0 references

cites work

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Targeting Angiogenesis in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

The vasculature in rheumatoid arthritis: cause or consequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Quantitative power Doppler ultrasonography is a sensitive measure of metacarpophalangeal joint synovial vascularity in rheumatoid arthritis and declines significantly following a 2-week course of oral low-dose corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Vascular endothelial growth factor: biology and therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Angiopoietin-like-4 is a potential angiogenic mediator in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Angiogenesis inhibition suppresses collagen arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Methionine aminopeptidase-2 blockade reduces chronic collagen-induced arthritis: potential role for angiogenesis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Adverse effects of anticancer agents that target the VEGF pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Bevacizumab increases risk for severe proteinuria in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Nephrotic syndrome after bevacizumab: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

"Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Immunohistochemical localisation of protein tyrosine kinase receptors Tie-1 and Tie-2 in synovial tissue of rheumatoid arthritis: correlation with angiogenesis and synovial proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Regulation of the angiopoietin-Tie ligand-receptor system with a novel splice variant of Tie1 reduces the severity of murine arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

The epidermal growth factor receptor pathway: a model for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Impact of EGFR expression on colorectal cancer patient prognosis and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Human epidermal growth factor for the stratification of synovial lining layer and neovascularisation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Targeted therapies in breast cancer: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Targeting the EGFR pathway for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Involvement of ErbB-2 in rheumatoid synovial cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Proinflammatory role of amphiregulin, an epidermal growth factor family member whose expression is augmented in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Antagonism of the human epidermal growth factor receptor family controls disease severity in murine collagen-induced arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Regulation of oxygen homeostasis by hypoxia-inducible factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Hypoxic-reperfusion injury in the inflamed human joint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Synovial proliferation differentially affects hypoxia in the joint cavities of rheumatoid arthritis and osteoarthritis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Hypoxia-induced upregulation of the glycolytic enzyme glucose-6-phosphate isomerase perpetuates rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Characterization of synovial tissue from arthritis patients: a proton magnetic resonance spectroscopic investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Oxidative damage in synovial tissue is associated with in vivo hypoxic status in the arthritic joint.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Synovial tissue hypoxia and inflammation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Hypoxia-inducible factor-1 as regulator of angiogenesis in rheumatoid arthritis - therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Hypoxia-inducible factor 1alpha is deregulated by the serum of rats with adjuvant-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Hypoxia upregulates angiogenesis and synovial cell migration in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Role of hypoxia-inducible factor-1alpha in hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Antitumor effects of 2-oxoglutarate through inhibition of angiogenesis in a murine tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Inhibition of HIF-1alpha activity by BP-1 ameliorates adjuvant induced arthritis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Rheumatoid arthritis: a disease associated with accelerated atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Cardiovascular disease in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Death rates and causes of death in patients with rheumatoid arthritis: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Patterns of cardiovascular risk in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

The specific contribution of hypoxia-inducible factor-2alpha to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

The risk of infections with biologic therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Synovial Hypoxia as a Cause of Tendon Rupture in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

The angiogenic pathway ?vascular endothelial growth factor/flk-1(KDR)-receptor? in rheumatoid arthritis and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis Correlation with disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

Neutralization of Vascular Endothelial Growth Factor Prevents Collagen-Induced Arthritis and Ameliorates Established Disease in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-011-9208-2

10.1007/S10456-011-9208-2

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21431303%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference